IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 1581 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (543 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References
   Article Tables

 Article Access Statistics
    Viewed1635    
    Printed15    
    Emailed0    
    PDF Downloaded53    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR: ARTICLES IN RESPONSE TO PREVIOUSLY PUBLISHED ARTICLES
Year : 2018  |  Volume : 84  |  Issue : 1  |  Page : 60-61

Author's reply


1 Department of Pharmacology, IPGME and R, Kolkata, India
2 Department of Dermatology, Bankura Sammilani Medical College, Bankura, West Bengal, India

Date of Web Publication26-Dec-2017

Correspondence Address:
Amrita Sil
Department of Pharmacology, UCM Building (1st floor), 244 AJC Bose Road, IPGME and R, Kolkata-20, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijdvl.IJDVL_894_17

Rights and Permissions



How to cite this article:
Sil A, Das N. Author's reply. Indian J Dermatol Venereol Leprol 2018;84:60-1

How to cite this URL:
Sil A, Das N. Author's reply. Indian J Dermatol Venereol Leprol [serial online] 2018 [cited 2020 May 28];84:60-1. Available from: http://www.ijdvl.com/text.asp?2018/84/1/60/221313


Sir,

We thank you for your critical appraisal of our study “Effectiveness and safety of levocetirizine 10 mg versus a combination of levocetirizine 5 mg and montelukast 10 mg in chronic urticaria resistant to levocetirizine 5 mg: A double-blind, randomized, controlled trial” by Sarkar et al.[1] We would like to clarify your doubts.

  1. Levocetirizine 10 mg one tablet in one group was compared to Levocetirizine 5 mg + Montelukast 10 mg one tablet in the other group. Thus, the participants of either group were given one tablet of either drug, keeping the blinding intact
  2. Clinical Trial Registry, India (CTRI) allows retrospective registration. However, ideally registration should be done prospectively. CTRI also takes some time to evaluate the proposal during registering, hence the time gap
  3. Both Urticaria Activity Score and Total Severity Score have been considered primary outcome measures, as mentioned in [Table 2] of the article with results discussed accordingly. For objectively measuring the nonresponders, we had to consider Total Severity Score as it includes the count of the antihistamines used and because Urticaria Activity Score does not include the criteria of antihistamines used, since as physicians, we were concerned about the pill burden. Total Severity Score has been used previously in studies by Bajaj et al.[2] and Sil et al.[3]
  4. The median price of levocetrizine 10 mg and levocetirizine 5 mg + montelukast 10 mg was compared from CIMS October–December, 2014 issue (at the time when the study was conducted). The cost of therapy was higher in levocetirizine 5 mg + montelukast 10 mg combination than levocetrizine 10 mg, as seen in [Table 1] below. Also, in [Table 2], when only the price of therapy of the trial medications (Levosiz 10 mg and Levosiz-M) was compared, the price of Levosiz M was 2.4 times more than Levosiz 10
  5. Because the study was designed as a superiority trial, the sample size was calculated based on detecting two-unit difference in Total Severity Score. We have mentioned that both the trial arms were “comparable in effectiveness.” Because the drugs were different molecules and not “me too” drug or drugs of the “same class,” we did not plan for an “equivalence” or “non-inferiority” trial.[4] Levocetirizine is an antihistamine whereas Montelukast is a leukotriene receptor antagonist. The article does not mention “equivalent” anywhere in the results or discussion. Moreover, the results (paragraph 3 of Results section) incorporate discussion on “between groups” analysis with the P values explicitly given in [Table 2] of the article.
Table 1: Price of trial medications

Click here to view
Table 2: Median price of levocetirizine 10 mg and levocetirizine + montelukast [references: Current Index of Medical Specialities, India (CIMS) 127 October, 2014]

Click here to view


We hope we have clarified your doubts and would be eager to reply to your comments. The research team would like to thank you for your keen interest in our study.

Thanking you.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Sarkar TK, Sil A, Pal S, Ghosh C, Das NK. Effectiveness and safety of levocetirizine 10 mg versus a combination of levocetirizine 5 mg and montelukast 10 mg in chronic urticaria resistant to levocetirizine 5 mg: A double-blind, randomized, controlled trial. Indian J Dermatol Venereol Leprol 2017;83:561-8.  Back to cited text no. 1
[PUBMED]  [Full text]  
2.
Bajaj AK, Saraswat A, Upadhyay A, Damisetty R, Dhar S. Autologous serum therapy in chronic urticaria: Old wine in a new bottle. Indian J Dermatol Venereol Leprol 2008;74:109-13.  Back to cited text no. 2
[PUBMED]  [Full text]  
3.
Sil A, Tripathi SK, Chaudhuri A, Das NK, Hazra A, Bagchi C, et al. Olopatadine versus levocetirizine in chronic urticaria: An observer-blind, randomized, controlled trial of effectiveness and safety. J Dermatolog Treat 2013;24:466-72.  Back to cited text no. 3
[PUBMED]    
4.
Lesaffre E. Superiority, equivalence, and non-inferiority trials. Bull NYU Hosp Jt Dis 2008;66:150-4.  Back to cited text no. 4
[PUBMED]    



 
 
    Tables

  [Table 1], [Table 2]



 

Top
Print this article  Email this article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow